Intellia Therapeutics Inc (NTLA) Institutional Buying & Selling Tracker (Q2 2026)

NTLA ranks #1898 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

NTLA is a disclosed holding of Cathie Wood (ARK Investment Management), one of the tracked superinvestors on AlphaSMO — it makes up 1.9% of that fund's own 13F portfolio.

NTLA is a top-conviction position for Regeneron Pharmaceuticals, Inc. — at 35.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in NTLA belongs to ARK Investment Management LLC, but the position matters far more to Regeneron Pharmaceuticals, Inc., who has 35.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

BlackRock has added to its NTLA position for two straight quarters, increasing it by $168.3M to reach $260.7M today.

Ken Griffin has trimmed its NTLA position for two straight quarters, cutting it by $5.9M while still holding $13.3M.

NTLA is up 0.6% today, and institutions have been net buyers of $649.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

NTLA reported a net loss of $400.0M over the trailing twelve months.

• Not yet profitable — net loss of $400.0M over the trailing twelve months
• Revenue grew 12.6% year over year
• Net income improved year over year, from -$480.2M to -$400.0M
• Operating cash flow was negative, using $394.7M in cash
• Current ratio of 5.08x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.25x equity — within a conventional range